18F-FDG PET can effectively rule out conversion to dementia and the presence of CSF biomarker of neurodegeneration: a real-world data analysis
Open accessThe DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Abstract
Background: Precisely defining the delay in onset of dementia is a particular challenge for early diagnosis. Brain [18 F] fluoro-2-deoxy-2-D-glucose (18 F-FDG) Positron Emission Tomography (PET) is a particularly interesting tool for the early diagnosis of neurodegenerative diseases, through the measurement of the cerebral glucose metabolic rate. There is currently a lack of longitudinal studies under real-life conditions, with sufficient patients, to accurately evaluate the predictive values of brain 18 F-FDG PET scans. Here, we aimed to estimate the value of brain 18 F-FDG PET for predicting the risk of dementia conversion and the risk of occurrence of a neurodegenerative pathology. Methods: Longitudinal data for a cohort of patients with no diagnosis of dementia at the time of recruitment referred by a tertiary memory clinic for brain 18 F-FDG PET were matched with (1) data from the French National Health Data System (NHDS), (2) data from the National Alzheimer Bank (NAB), and (3) lumbar puncture (LP) biomarker data. The criteria for dementia conversion were the designation, within the three years after the brain 18 F-FDG PET scan, of a long-term condition for dementia in the NHDS and a dementia stage of cognitive impairment in the NAB. The criterion for the identification of a neurodegenerative disease in the medical records was the determination of LP biomarker levels. Results: Among the 403 patients (69.9 ± 11.4 years old, 177 women) from the initial cohort with data matched with the NHDS data, 137 were matched with the NAB data, and 61 were matched with LP biomarker data. Within three years of the scan, a 18 F-FDG PET had negative predictive values of 85% for dementia conversion (according to the NHDS and NAB datasets) and 95% for the presence of LP neurodegeneration biomarkers. Conclusion: A normal brain 18 F-FDG PET scan can help rule out the risk of dementia conversion and the presence of cerebrospinal fluid (CSF) biomarker of neurodegeneration early with high certainty, allowing modifications to patient management regimens in the short term. Trial registration: Clinical Trials database (NCT04804722). March 18, 2021. Retrospectively registered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Since CSF collection is invasive, positron emission tomography (PET) and magnetic resonance imaging (MRI) scans are used as noninvasive methods to detect metabolic and structural brain changes associated with AD [221,222,223].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [221]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Dementia prevention, intervention, and care
Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames, D., Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31363-6 · Cited by 6,072
Cuschieri, S. (2019) · Saudi Journal of Anaesthesia · doi:10.4103/sja.sja_543_18 · Cited by 4,331 · cited 1×
“The STROBE statement [17] was used as a reporting guide for the present article.”
Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Feldman, H. H., Frisoni, G. B., Hampel, H., Jagust, W. J., Johnson, K. A., Knopman, D. S., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002923 · Cited by 1,864
Clinical diagnosis of Alzheimer’s disease: Recommendations of the International Working Group
Dubois, B., Villain, N., Frisoni, G. B., Rabinovici, G. D., Sabbagh, M., Cappa, S., Bejanin, A., Bombois, S., Epelbaum, S., Teichmann, M., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00066-1 · Cited by 1,051 · cited 1×
“Currently, postmortem autopsy remains the only way to confirm a diagnosis of a neurodegenerative disease [2, 7].”
Silverman, D. H. S., Small, G. W., Chang, C. Y., Lu, C. S., de Aburto, M. A. K., Chen, W., Czernin, J., Rapoport, S. I., Pietrini, P., Alexander, G. E., et al. (2001) · JAMA · doi:10.1001/jama.286.17.2120 · Cited by 951
Chételat, G., Arbizu, J., Barthel, H., Garibotto, V., Law, I., Morbelli, S., van de Giessen, E., Agosta, F., Barkhof, F., Brooks, D. J., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30314-8 · Cited by 526
Mosconi, L. (2013) · Clinical and Translational Imaging · doi:10.1007/s40336-013-0026-y · Cited by 328
Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET.
Drzezga, A. E., Grimmer, T., Riemenschneider, M., Lautenschlager, N. T., Siebner, H. R., Alexopoulus, P., Minoshima, S., Schwaiger, M., & Kurz, A. (2005) · UWA Profiles and Research Repository (UWA) · Cited by 319
Research works printed but not linked: 1
- Jellinger KA. Pathology and pathogenesis of vascular cognitive impairment—a critical update. Front Aging Neurosci [Internet]. 2013 [cited 2023 Nov 27];5. http://journal.frontiersin.org/article/https://doi.org/10.3389/fnagi.2013.00017/abstract. · doi:10.3389/fnagi.2013.00017/abstract
Cited by
Christodoulou, R. C., Eller, D., Papageorgiou, P. S., Angelopoulou, E., Vassiliou, E. K., & Papageorgiou, S. G. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15051884 · Cited by 25
Morbelli, S. D., Weehaeghe, D. V., Verger, A., Tolboom, N., Fernandez, P. A., Brendel, M., Guedj, É., Garibotto, V., Cecchin, D., Yakushev, I. Y., et al. (2025) · The EANM Journal · doi:10.1016/j.eanmj.2025.100005 · Cited by 8
Self-citationNeuroimaging Biomarkers in Alzheimer’s Disease
Tripathi, S. M., Chutia, P., & Murray, A. D. (2025) · Journal of dementia and Alzheimer's disease · doi:10.3390/jdad2040037 · Cited by 8
Lu, H., Yang, R., Cao, D., Du, S., & Liu, M. (2024) · ACS Applied Nano Materials · doi:10.1021/acsanm.4c06056 · Cited by 7
Gu, S., & Ran, C. (2025) · iRadiology · doi:10.1002/ird3.70002 · Cited by 5
Metadata
- Authors
- Heyer, S., Simon, M., Doyen, M., Mortada, A., Roch, V., Jeanbert, E., Thilly, N., Malaplate, C., Kearney-Schwartz, A., Jonveaux, T., Bannay, A., & Verger, A.
- Affiliations
- Centre Hospitalier Régional et Universitaire de Nancy (FR)
- Inserm (FR)
- Corresponding author
- Verger, Antoine
- ORCID
- Venue
- Alzheimer's Research & Therapy
- Published
- 2024-08-13
- Volume
- 16
- Issue
- 1
- Pages
- 182-182
- ISSN
- 1758-9193 (ISSN-L)
- PMC
- PMC11320856
- OpenAlex
- W4401542515
- Cited by
- 14
- References
- 31
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 2
- FWCI
- 4.12
- Type
- journal article
- Language
- en
- Update notices
- correction (2024-11-13)
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Alzheimer s Research & Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- 18F-FDG PET, conversion to dementia, neurodegeneration, cerebrospinal fluid biomarkers, negative predictive value, early diagnosis, brain glucose metabolism, longitudinal follow-up, memory clinic patients, Alzheimer's disease, real-world data, cognitive impairment
- MeSH terms
- Aged, Aged, 80 and over, Brain, Dementia, Female, Humans, Longitudinal Studies, Male, Middle Aged, Cohort Studies, Biomarkers, Amyloid beta-Peptides, tau Proteins, Disease Progression, Neurodegenerative Diseases, Fluorodeoxyglucose F18, Early Diagnosis, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 18F-FDG PET can effectively rule out conversion to dementia and the presence of CSF biomarker of neurodegeneration: a real-world data analysis. https://app.cochat.ai/papers/10.1186/s13195-024-01535-3
- The paper
- Heyer, S., Simon, M., Doyen, M., Mortada, A., Roch, V., Jeanbert, E., Thilly, N., Malaplate, C., Kearney-Schwartz, A., Jonveaux, T., Bannay, A., & Verger, A. (2024). 18F-FDG PET can effectively rule out conversion to dementia and the presence of CSF biomarker of neurodegeneration: a real-world data analysis. Alzheimer's Research & Therapy. https://doi.org/10.1186/s13195-024-01535-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.